Alcon has entered into a definitive merger agreement to acquire Aerie Pharmaceuticals in a deal worth approximately $770 million, according to a press release.
With the merger, Alcon will acquire Rocklatan (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution) and Rhopressa (netarsudil 0.02% ophthalmic solution), both indicated for the reduction of elevated IOP in open-angle glaucoma or ocular hypertension, as well as AR-15512, a phase 3 product candidate for dry eye disease, and a pipeline of clinical and preclinical ophthalmic pharmaceutical product candidates, the release said.
The